GO:0004823 leucine-tRNA ligase activity: Mechanism, Genes

GO:0004823, leucine-tRNA ligase activity, is a molecular function that ensures the correct pairing of the amino acid leucine with its cognate transfer RNA during protein synthesis. This activity is carried out by leucyl-tRNA synthetase (LeuRS), which belongs to the class I aminoacyl-tRNA synthetase family and is conserved from bacteria to humans. The reaction consumes ATP and produces Leu-tRNA(Leu), which delivers leucine to the ribosome for incorporation into nascent polypeptides. Because leucine is one of the most abundant amino acids in proteins, accurate Leu-tRNA synthesis is critical for proteome integrity and cellular homeostasis. Beyond translation, leucine-tRNA ligase activity has emerged as a signaling node that communicates amino acid availability to growth-regulatory pathways such as mTORC1. In mammalian cells, the enzyme LARS1 (leucyl-tRNA synthetase 1) acts as a leucine sensor and regulates autophagy and lysosomal function. Consequently, researchers study GO:0004823 not only as a housekeeping translation factor but also as a potential therapeutic target in cancer and neurodegenerative disease. This article integrates the QuickGO definition with verified literature to provide a research-grade overview of the mechanism, genes, disease links, and experimental models relevant to leucine-tRNA ligase activity.

Leucine-tRNA ligase activity (GO:0004823) is defined by QuickGO as the catalysis of the reaction: leucine + ATP + tRNA(Leu) = AMP + diphosphate + 2 H+ + Leu-tRNA(Leu). In other words, it is the enzymatic activity that charges tRNA(Leu) with the amino acid leucine, using ATP as an energy source and releasing AMP and diphosphate. This activity is synonymous with leucyl-tRNA synthetase activity, leucine translase activity, and leucyl-transfer RNA synthetase activity, among other names.

Leucine-tRNA ligase activity is fundamental to protein synthesis because it ensures that leucine is accurately incorporated into proteins according to the genetic code. Errors in this process can lead to mistranslation, protein misfolding, and cellular stress, which are associated with disease. In addition to its canonical role, the enzyme LARS1 functions as a leucine sensor that regulates mTORC1 signaling and autophagy, thereby influencing cell growth and survival. These dual roles make GO:0004823 a compelling target for understanding cancer metabolism and neurodegeneration.

The following genes and proteins are directly or indirectly associated with leucine-tRNA ligase activity and its regulation.

Leucine-tRNA ligase activity is regulated at multiple levels. The expression of LARS1 is controlled by nutrient availability and stress signals, and its activity can be modulated by post-translational modifications. In particular, LARS1 functions as a leucine sensor in the mTORC1 pathway, where it interacts with Rag GTPases to promote mTORC1 activation in the presence of leucine. This regulation connects leucine-tRNA ligase activity to autophagy, as LARS1 also participates in the regulation of autophagosome formation. Additionally, the integrated stress response can influence aminoacyl-tRNA synthetase expression to adapt to changing metabolic conditions.

In intrahepatic cholangiocarcinoma, overexpression of LARS1 restores N-glycosylation and promotes chemoresistance. Targeting LARS1 or its downstream pathways may sensitize tumors to chemotherapy. This highlights leucine-tRNA ligase activity as a potential therapeutic target in cancer.

Dysregulation of autophagy is a hallmark of Parkinson's disease, and LARS1 is involved in autophagy regulation. Small-molecule compounds that target autophagy pathways may modulate leucine-tRNA ligase activity indirectly. Further research is needed to establish direct links between LARS1 mutations and neurodegeneration.

Mutations in LARS2, the mitochondrial leucyl-tRNA synthetase, can cause mitochondrial translation defects and are associated with conditions such as Perrault syndrome. These mutations impair leucine-tRNA ligase activity in mitochondria, leading to energy deficiency.

Ribo-seq measures ribosome occupancy and can reveal changes in translation efficiency of leucine codons upon modulation of leucine-tRNA ligase activity. This method is useful for detecting global translation defects in LARS1 knockout or mutant cells.

RNA-seq quantifies transcript abundance and can identify compensatory changes in aminoacyl-tRNA synthetase genes when leucine-tRNA ligase activity is altered. It is often combined with Ribo-seq to separate transcriptional from translational effects.

Mass spectrometry-based proteomics can detect mistranslation events and changes in protein expression resulting from altered leucine-tRNA ligase activity. Amino acid analysis can measure intracellular leucine levels.

Fluorescently tagged LARS1 or tRNA(Leu) reporters can visualize localization and dynamics in live cells. Luciferase-based reporters can monitor mTORC1 activity downstream of leucine sensing.

Researchers studying leucine-tRNA ligase activity-related genes often need to determine whether a candidate gene is causally involved in translation fidelity, drug resistance, or autophagy. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models for such investigations.

Leucine-tRNA ligase activity (GO:0004823) is a cornerstone of protein synthesis and a key node in nutrient sensing and disease. Its dual role in translation and mTORC1 signaling makes it a compelling target for cancer and neurodegeneration research. By leveraging CRISPR models and multi-omics methods, researchers can dissect the precise contributions of LARS1 and related genes to human health.